Skip to main content

Table 5 Demographic and clinical characteristics of ET patients

From: The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

  JAK2V617F negative JAK2 V617F positive  
  GCC genotype GCC genotype Pvalue
  No ( n = 19) Yes ( n = 23) No ( n = 22) Yes ( n = 35)  
Age, mean (SD) 51.2 (18.3) 57.9 (17.5) 64.8 (14.9) 66.1 (16.2) 0.6466
Sex      
   Female 10 (52.6%) 14 (60.9%) 8 (36.4%) 22 (62.9%) 0.2965
   Male 9 (47.4%) 9 (30.1%) 14 (64.6%) 13 (37.1%)  
Splenomegaly 11/16 (68.8%) 4/22 (18.2%) 5/20 (25%) 4/33 (12.1%) 0.0448*
Thrombosis 0/11 (0%) 5/21 (23.8%) 6/17 (35.3%) 7/30 (23.3%) 0.0446*
Therapy requirement 10/16 (90%) 15/22 (68.2%) 7/21 (33.3%) 25/34 (73.5%) 0.7408
Cytogenetic abnormality 1/8(0%) 0/16 (0%) 2/9 (22.2%) 4/21(19%) 0.3618
MF evolution 0/16 (0%) 1/22 (4.5%) 0/15 (0%) 1/30 (3.3%) 0.3787
AML evolution 0/11 (0%) 1/22 (4.5%) 0/15 (0%) 0/30 (0%) 0.7343
Survival, mean (SD) 2036 (2267) 1883 (1643) 1706 (1847) 1717 (292) 0.6528
  1. Statistical analysis was done among four groups.
  2. P value is obtained from multivariate analysis.
  3. Asterisks indicate statistically significant values.